University of North Carolina Health Care Mar 13 2025 Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs) found that patients responded better to a combination of two immunotherapies than patients who received just one immunotherapy drug. The scientists also analyzed immune cells in each person's tumor after one month of immunotherapy to see which type of immune cells were activated to fight their cancer, suggesting that